Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of C34-CXCR4-modified T-cells in HIV
NCT03020524Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Jan 2017
- Primary completion
- Nov 2019
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of C34-CXCR4-modified autologous CD4+ T-cells in human immunodeficiency virus infection (HIV) (3 arms), sponsored by University of Pennsylvania. Primary endpoint: Number of Subjects With Treatment Related Adverse Events at 1 year. Started Jan 2017; status: completed.
02
Drugs
C34-CXCR4-modified autologous CD4+ T-cells
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03020524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020524.